Tag Archives: industry trends

Watch-Out Tech Industry, Biotech is on the Rise in San Francisco

Golden Gate Bridge San Francisco, CA

When thinking about the industries that make up San Francisco’s vibrant economy, biopharma is often overshadowed by the Bay Area’s reputation as a tech hotspot. But in reality, health care outpaced the tech sector in 2014 by generating over $28 billion in economic activity and employing over 20% of San Francisco workers. The Bay Area is a hub of innovation for growing biotechs looking to connect with the right investors, which is why BIO chose Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Life Science Leader Asks: What Biopharma Trends Should Pharma Execs Be Paying Attention To?

Life Science Leader

In my last installment of this four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & Associates, I asked what trends should biopharma execs be paying greater attention to and why. Check out my interview to get insights from Peter on upcoming trends! Peter’s session, Inventing Your Own Hub: Evolving Institutional Models for Translational Medicine, will be taking plan June 16 from 3:30 p.m.-4:45 p.m. in room 105AB. If you missed the earlier segments in this series, here is Part 1, Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

State of the Industry for Emerging Therapeutic Companies

Emerging Therapeutic Company Investment and Deal Trends

Emerging therapeutic companies are at their strongest point in a decade. In our new report on investment and deal trends, the BIO Industry Analysis team shows how this segment within the biotech industry has been faring over the last 10 years. The annual aggregate totals show that for almost every funding or deal activity analyzed, 2014 was the peak year of the last decade. A strong public market, a revitalized private funding environment, and a Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Big Ventures

It is rare to see triple digit millions in private financing rounds, but it does happen once or twice a year on average. In the headlines last week, was the largest triple digit VC round in years – the $160M in venture capital funding for Intarcia. With the simultaneous debt financing of $50M, the total funding round was $210M. Behind the deal were existing investors New Enterprise Associates, New Leaf Venture Partners and Venrock, plus Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The Good, the Bad, and the Ugly for Biotech IPOs


The troubles in the biotech IPO market are complicated to explain to industry outsiders. They read about new biotechs debuting on the public market, but also hear bankers, VCs, and CEOs complaining about how the IPO window never really opened after 2008. The reality is that we are seeing positive developments and negative trends simultaneously. On the bright side, the cumulative number of IPOs is holding up. The recent pace of biotech IPOs mimics what Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,